Biogen Inc. (NASDAQ:BIIB) Shares Bought by Savant Capital LLC

Savant Capital LLC raised its position in Biogen Inc. (NASDAQ:BIIB) by 11.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,179 shares of the biotechnology company’s stock after acquiring an additional 423 shares during the period. Savant Capital LLC’s holdings in Biogen were worth $639,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Pacer Advisors Inc. raised its holdings in shares of Biogen by 13,574.7% in the fourth quarter. Pacer Advisors Inc. now owns 2,667,531 shares of the biotechnology company’s stock worth $407,919,000 after buying an additional 2,648,024 shares during the last quarter. International Assets Investment Management LLC raised its holdings in shares of Biogen by 19,722.9% in the third quarter. International Assets Investment Management LLC now owns 358,992 shares of the biotechnology company’s stock worth $695,870,000 after buying an additional 357,181 shares during the last quarter. Mizuho Securities USA LLC raised its holdings in shares of Biogen by 2,715.9% in the third quarter. Mizuho Securities USA LLC now owns 316,000 shares of the biotechnology company’s stock worth $61,253,000 after buying an additional 304,778 shares during the last quarter. Erste Asset Management GmbH purchased a new position in shares of Biogen in the third quarter worth $55,826,000. Finally, State Street Corp raised its holdings in shares of Biogen by 3.5% in the third quarter. State Street Corp now owns 7,344,960 shares of the biotechnology company’s stock worth $1,423,747,000 after buying an additional 248,942 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have issued reports on BIIB shares. Canaccord Genuity Group decreased their price target on shares of Biogen from $298.00 to $265.00 and set a “buy” rating for the company in a report on Thursday. Wells Fargo & Company reduced their target price on shares of Biogen from $165.00 to $140.00 and set an “equal weight” rating for the company in a report on Thursday. TD Cowen reduced their target price on shares of Biogen from $300.00 to $275.00 and set a “buy” rating for the company in a report on Thursday, October 31st. Sanford C. Bernstein initiated coverage on shares of Biogen in a report on Tuesday, February 11th. They set a “market perform” rating and a $160.00 target price for the company. Finally, StockNews.com cut shares of Biogen from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 28th. Seventeen investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $211.96.

Biogen Stock Performance

BIIB opened at $137.33 on Friday. The firm has a market capitalization of $20.01 billion, a PE ratio of 12.41, a PEG ratio of 1.65 and a beta of -0.08. Biogen Inc. has a twelve month low of $128.51 and a twelve month high of $238.00. The firm’s 50-day moving average price is $146.90 and its 200 day moving average price is $173.26. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.28.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, topping analysts’ consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.81% and a return on equity of 14.98%. As a group, sell-side analysts expect that Biogen Inc. will post 16.42 EPS for the current fiscal year.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.